Vasoregulation by the Cav1.2 channel C-terminus
Cav1.2 通道 C 端的血管调节
基本信息
- 批准号:8531708
- 负责人:
- 金额:$ 5.22万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-07-01 至 2015-06-30
- 项目状态:已结题
- 来源:
- 关键词:AgonistArteriesAttenuatedBindingBiological AssayBiotinylationBlood PressureBlood VesselsBlood flowBrainC-terminalCalciumCaliberCalmodulinCardiac MyocytesCell membraneCerebrumCleaved cellCoupledDataDetectionElectrophysiology (science)EndothelinEndothelin-1Energy TransferEnsureExhibitsFluorescence MicroscopyFura-2GenesGenetic TranscriptionGlassGoalsImageImmunofluorescence ImmunologicIon ChannelKnowledgeL-type calcium channel alpha(1C)LengthLuc GeneMeasurementMeasuresMembraneMembrane PotentialsMembrane ProteinsMessenger RNAMethodsMicroelectrodesMuscle CellsMyographyMyosin Light Chain KinaseNeuronsNuclearPhospholipase CPhysiologicalPlayProtein FragmentProtein KinaseProteinsPurinoceptorRNA InterferenceRecombinantsRegional Blood FlowRegulationReporterResearchResistanceRoleSignal PathwaySmooth Muscle MyocytesStimulusSurfaceTechniquesTestingTimeTranscriptUridineVasoconstrictor AgentsVasodilationVasodilator AgentsWestern BlottingWorkcapillary bedcerebral arterychannel blockersconstrictionmutantnoveloverexpressionpatch clamppressureratiometricresearch studystemtripolyphosphatevasoconstrictionvoltage
项目摘要
DESCRIPTION (provided by applicant): Resistance-size cerebral arteries modulate brain regional blood pressure and flow. Arterial smooth muscle cell voltage-dependent calcium (CaV1.2) channels are key regulators of vascular contractility. Vascular CaV1.2 channels are activated by membrane depolarization and vasoconstrictor agonists, leading to an increase in intracellular calcium ([Ca2+]i) concentration and vasoconstriction. CaV1.2 channels can undergo enzymatic cleavage, yielding truncated, short-form CaV1.2 channels and a C-terminal protein fragment (CCT). Whether CCT exists in arterial smooth muscle cells and regulates vascular contractility is unclear. This application stems from novel preliminary data indicating that CCT exhibits nuclear localization and attenuates functional CaV1.2 expression in cerebral artery smooth muscle cells. Preliminary data also indicate that vasoconstrictors reduce CCT protein to elevate CaV1.2 channel expression and induce vasoconstriction. The central hypothesis of this proposal is that the CCT controls functional CaV1.2 channel expression and plasma membrane currents in cerebral artery smooth muscle cells. Aim 1 will investigate the hypothesis that the truncated CaV1.2 channel C-terminus inhibits CaV1.2transcription, surface CaV1.2 channel expression, and CaV1.2currents in arterial smooth muscle cells. Aim 2 will examine the hypothesis that vasoconstrictors control CaV1.2 channel expression and activity by modulating the total amount and nuclear localization of CCT in arterial smooth muscle cells. Aim 3 will test the hypothesis that the CCT regulates arterial smooth muscle cell [Ca2+]i, thereby modulating contractility. Techniques to be used include real-time PCR, Western blotting, expression of recombinant CCT, RNA interference, immunofluorescence and immunofluorescence resonance energy transfer (immunoFRET), patch-clamp electrophysiology, calcium imaging, and pressurized artery myography. This research will reveal novel mechanisms of vascular contractility regulation by the CaV1.2 channel C-terminus.
描述(由申请人提供):电阻大小的大脑动脉调节大脑区域血压和流动。动脉平滑肌细胞电压依赖性钙(CAV1.2)通道是血管收缩力的关键调节剂。血管CAV1.2通道通过膜去极化和血管收缩激动剂激活,导致细胞内钙([Ca2+] i)浓度和血管收缩的增加。 CAV1.2通道可以进行酶促切割,产生截短的短形式CAV1.2通道和C末端蛋白质片段(CCT)。 CCT是否存在于动脉平滑肌细胞中并调节血管收缩力尚不清楚。该应用源于新的初步数据,表明CCT表现出核定位,并减弱脑动脉平滑肌细胞中的功能性CAV1.2表达。初步数据还表明,血管收缩剂减少CCT蛋白以升高CAV1.2通道表达并诱导血管收缩。该提议的中心假设是CCT控制脑动脉平滑肌细胞中的功能性CAV1.2通道表达和质膜电流。 AIM 1将研究截短的CAV1.2通道C末端抑制CAV1.2转录,表面CAV1.2通道表达和CAV1.2电流的假设。 AIM 2将检查以下假设:血管收缩剂通过调节CCT在动脉平滑肌细胞中CCT的总量和核定位来控制CAV1.2通道表达和活性。 AIM 3将检验CCT调节动脉平滑肌细胞[Ca2+] I的假设,从而调节收缩力。要使用的技术包括实时PCR,Western印迹,重组CCT的表达,RNA干扰,免疫荧光和免疫荧光共振能量转移(Immunofret),斑块钳电生理学,钙成像和压缩动脉me摄影。这项研究将揭示CAV1.2通道C末端调节血管收缩性调节的新型机制。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Kirk W Evanson其他文献
Kirk W Evanson的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Kirk W Evanson', 18)}}的其他基金
Vasoregulation by the Cav1.2 channel C-terminus
Cav1.2 通道 C 端的血管调节
- 批准号:
8397366 - 财政年份:2012
- 资助金额:
$ 5.22万 - 项目类别:
Vasoregulation by the Cav1.2 channel C-terminus
Cav1.2 通道 C 端的血管调节
- 批准号:
8692594 - 财政年份:2012
- 资助金额:
$ 5.22万 - 项目类别:
相似国自然基金
多种动脉硬化标志物顺序响应型探针的构建及精准成像应用研究
- 批准号:22368035
- 批准年份:2023
- 资助金额:32 万元
- 项目类别:地区科学基金项目
中性胆固醇酯水解酶1(NCEH1)在肺动脉高压发生发展中的重要作用及机制研究
- 批准号:82300074
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
二甲基化促进棕榈酰化修饰调控DPP4蛋白酶活性在主动脉瓣钙化中的作用及机制研究
- 批准号:82370379
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
靶向递送miR-140-5p过表达间充质干细胞外泌体治疗肺动脉高压的研究
- 批准号:82370059
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
左心内皮细胞Piezo1激活EDN1/HIF通路诱导左心疾病所致肺动脉高压的机制研究
- 批准号:82300067
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Therapeutic Strategies for Microvascular Dysfunction in Type 1 Diabetes
1 型糖尿病微血管功能障碍的治疗策略
- 批准号:
10590208 - 财政年份:2023
- 资助金额:
$ 5.22万 - 项目类别:
Fibroblast growth factor 1 prevents hyperlipidemia and atherosclerosis
成纤维细胞生长因子 1 预防高脂血症和动脉粥样硬化
- 批准号:
10345440 - 财政年份:2021
- 资助金额:
$ 5.22万 - 项目类别:
Drug Repurposing to Accelerate Progress in Neonatal Neuroprotection
药物再利用加速新生儿神经保护的进展
- 批准号:
10300790 - 财政年份:2021
- 资助金额:
$ 5.22万 - 项目类别:
Opioid-induced potentiation of the exercise pressor reflex via acid-sensing ion channels (ASIC3) in health and simulated peripheral artery disease
阿片类药物通过酸敏感离子通道 (ASIC3) 在健康和模拟外周动脉疾病中诱导运动升压反射增强
- 批准号:
10593184 - 财政年份:2021
- 资助金额:
$ 5.22万 - 项目类别:
Drug Repurposing to Accelerate Progress in Neonatal Neuroprotection
药物再利用加速新生儿神经保护的进展
- 批准号:
10454287 - 财政年份:2021
- 资助金额:
$ 5.22万 - 项目类别: